<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10762457</PMID>
      <DateCompleted>
        <Year>2000</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0954-6820</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>247</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2000</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of internal medicine</Title>
          <ISOAbbreviation>J Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chlamydia pneumoniae in atherosclerosis.</ArticleTitle>
        <Pagination>
          <StartPage>391</StartPage>
          <EndPage>396</EndPage>
          <MedlinePgn>391-6</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Chlamydia pneumoniae is currently the infectious agent most often associated with the inflammation found in atherosclerosis. The seroepidemiological association and the actual presence of pathogen in lesions has been confirmed in numerous studies, in which technical difficulties seem to be the only limitation. Besides animal experiments and intervention trials, we need information of possible pathogenic mechanisms. Recently, several studies have suggested mechanisms by which C. pneumoniae infection could participate in the development of atherosclerosis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Saikku</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>KTL, National Public Health Institute, Department in Oulu, Oulu, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Intern Med</MedlineTA>
        <NlmUniqueID>8904841</NlmUniqueID>
        <ISSNLinking>0954-6820</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000942">Antigens, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018834">Chaperonin 60</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004731">Endotoxins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000942" MajorTopicYN="N">Antigens, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001161" MajorTopicYN="N">Arteriosclerosis</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018834" MajorTopicYN="N">Chaperonin 60</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002690" MajorTopicYN="N">Chlamydia Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016993" MajorTopicYN="Y">Chlamydophila pneumoniae</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004731" MajorTopicYN="N">Endotoxins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>66</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2000</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2000</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2000</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">10762457</ArticleId>
        <ArticleId IdType="doi">10.1046/j.1365-2796.2000.00659.x</ArticleId>
        <ArticleId IdType="pii">jim659</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
